No Detail Found!

Lefamulin - upgrading our arsenal against community- acquired pneumonia

Author(s)
Indiraa Priyadharshini Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre,Chennai, Tamil Nadu,India
Vasanth Konda Mohan Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre,Chennai, Tamil Nadu,India
Melvin George Department of Clinical Pharmacology, SRM Medical College Hospital and Research Centre,Chennai, Tamil Nadu,India
Abstract
Lefamulin (formerly BC-3781) is a novel semi-synthetic pleuromutilin antibiotic that has been granted marketing authorization in the US for the treatment of patients with Community-acquired bacterial pneumonia (CABP). It shows potent in vitro activity against atypical and typical pathogens that cause CABP. Lefamulin interferes with the peptidyl transferase center and inhibits the prokaryotic ribosomal protein synthesis. This is achieved through its binding at the A- and P-site of the 50S ribosomal submit, resulting in the interruption of peptide bond formation. This is a novel mechanism for inhibiting bacterial peptide chain elongation. By virtue of its favorable clinical response and reasonable safety data in two non-inferiority phase III clinical trials (Lefamulin Evaluation against Pneumonia - LEAP1 & LEAP2 trials), the drug has been granted regulatory approval. The drug is highly bound to plasma protein and the mean half-life is 8 hours. The drug is metabolized by cytochrome P450 (CYP450) enzyme. This narrative review discusses the efficacy, safety, pharmacokinetics, and current status of lefamulin in the management of CABP.
Publication Details
Page(s) 96-100
DOI DOI not available
Published Journal: Archives of Pharmacy Practice, Volume: 11, Issue: 3, Year: 2020

Request the full text from PASTIC

Keywords
LEAP1, community-acquired bacterial pneumonia, LEAP2, Lefamulin
References
Mackenzie G. .2016 .The definition and classification of pneumonia. Pneumonia (Nathan), 8 : 14.
Khaky B,Yazdannik A,Mahjoubipour H,Attari F. .2018 .The Effect of Oral Decontamination Plan on The Occurrence Of Ventilator Associated Pneumonia in Icu Patients: A Double-Blind Clinical Trial. , 6(1) : 12-6.
Qusti SY,Alseeni MN,Alharbi RA,Balgoon M,Jambi EJ,Alotaibi SA .2018 .Antibacterial Activity of Selected Plants Species Extract Cited in the Holy Quran Against Clinical Isolates. Pharmacophores, 9(5) : 18-28.
Mahendra M,Jayaraj BS,Limaye S,Chaya SK,Dhar R,Mahesh PA .2018 .Factors influencing severity of community-acquired pneumonia. Lung India, 35(4) : 284-289.
Thoracic American,Society American .2005 .Infectious Diseases of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med, 171(4) : 388-416.
Feldman C,Anderson R .2016 .The Role of Streptococcus pneumoniae in Community-Acquired Pneumonia. Semin Respir Crit Care Med, 37(6) : 806-818.
Forstner C,Rohde G,Rupp J .2016 .Community-acquired Haemophilus influenzae pneumonia--New insights from the CAPNETZ study. J Infect, 72(5) : 554-563.
Ariza-Prota MA,Pando-Sandoval A,García-Clemente M,FoleVázquez D .2016 .Community-Acquired Moraxella catarrhalis Bacteremic Pneumonia: Two Case Reports and Review of the Literature. Case Rep Pulmonol, : 5134969.
Ahamed Thanish,Lakshmi S,Antibacterial T. .2018 .Activity of Taxifolin Isolated from Acacia Catechu Leaf Extract-An in Vitro Study. Int. J. Pharm. Res. Allied Sci, 7(4) : 133-7.
Henriques-Normark B,Tuomanen EI .2013 .The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring HarbPerspect Med, 3(7) : a010215.
Dion CF,Ashurst JV,Island (FL): StatPearls Publishing JV . .. Streptococcus Pneumoniae. [Updated 2020 Mar, 25 : .
Cherazard R,Epstein M,Doan TL,Salim T,Bharti S,Smith MA .2017 .Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications. Am J Ther, 24(3) : e361-e369.
Tristram S,Jacobs MR,Appelbaum PC .2007 .Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev, 20(2) : 368-89.
Mojgani N,Rahbar M,Taqizadeh M,Ashtiani MP,Mohammadzadeh M .2011 .Biotyping, capsular typing, and antibiotic resistance pattern of Haemophilus influenzae strains in Iran. Japan J Infect Dis, 64(1) : 66-8.
Li XX,Xiao SZ,Gu FF,He WP,Ni YX,Han LZ .2020 .Molecular Epidemiology and Antimicrobial Resistance of Haemophilus influenzae in Adult Patients in Shanghai, China. , 8 : 95.
Hare KM,Seib KL,Chang AB,Harris TM,Spargo JC,SmithVaughan HC .2019 .Antimicrobial susceptibility and impact of macrolide antibiotics on Moraxella catarrhalis in the upper and lower airways of children with chronic endobronchial suppuration. J Med Microbiol, 68(8) : 1140-1147.
Liu Y,Xu H,Xu Z .2015 .High-Level Macrolide-Resistant Moraxella catarrhalis and Development of an Allele-Specific PCR Assay for Detection of 23S rRNA Gene A2330T Mutation: A Three-Year Study at a Chinese Tertiary Hospital. Microb Drug Resist, 21(5) : 507-511.
Du Y,Zhou H,Wang F .2017 .Multilocus sequence typing-based analysis of Moraxella catarrhalis population structure reveals clonal spreading of drug-resistant strains isolated from childhood pneumonia. Infect Genet Evol, 56 : 117-124.
Lhommet C,Garot D,Grammatico-Guillon L .2020 .Predicting the microbial cause of community-acquired pneumonia: can physicians or a data-driven method differentiate viral from bacterial pneumonia at patient presentation?. BMC Pulm Med, 20(1) : 62.
Randhawa MA,Bawadekji A,Al Ali M,Oueslati MH,Basha JW,Including MRSA .2018 .Multidrug Resistant Acinetobacter Baumannii. Int. J. Pharm. Phytopharm. Res, 8(4) : 1-5.
Perry W,Golan Y .2019 .Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia. Future Microbiol, 14 : 927-939.
Rodvold KA .2019 .Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. J Antimicrob Chemother, 74(Suppl 3) : iii2-iii4.
Paukner S,Riedl R .2017 .Potent Drugs for Resistant BugsMode of Action and Resistance. Cold Spring HarbPerspect Med, 7(1) : a027110.
Eyal Z,Matzov D,Krupkin M .2016 .Published 2016 Dec 13. Sci Rep, 6 : 39004.
Birch AJ,Holzapfel CW,Richards RW .1963 .Diterpenoid nature of pleuromutilin. Chem Ind, 5 : 374-375.
Lin J,Zhou D,Steitz TA,Polikanov YS,Gagnon MG .2018 .RibosomeTargeting Antibiotics: Modes of Action, Mechanisms of Resistance, and Implications for Drug Design. Annu Rev Biochem, 87 : 451-478.
Wicha WW,Prince WT,Lell C,Heilmayer W,Gelone SP .2019 .Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, 74(Suppl 3) : iii19-iii26.
Paukner S,Sader HS,Ivezic-Schoenfeld Z,Jones RN .2013 .Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother, 57 : 4489e95.
Sader HS,Paukner S,Ivezic-Schoenfeld Z,Biedenbach DJ,Schmitz FJ,Jones RN .2012 .Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for communityacquired respiratory tract infections (CARTIs). J Antimicrob Chemother, 67 : 1170e5.
Koulenti D,Xu E,Yin Sum Mok I .2019 ."Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. , 7(10) : 386.
File TM,Goldberg L,Das A .2019 .Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis, 69(11) : 1856-1867.
Alexander E,Goldberg L,Das AF .2019 .Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial [published online ahead of print, 2019 Sep 27]. , 322(17) : 1661-1671.
Sandrockc . .Safety and Tolerability of Lefamulin vs Moxifloxacin in Adults with Community-Acquired Bacterial Pneumonia: Results of the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Double-Blind Noninferiority Phase-3 Clinical Trials. Chest Annual Meeting 2019 Oct 19-23, : .
Zhang L,Wicha WW,Bhavnani SM,Rubino CM SM .2019 .Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods. J Antimicrob Chemother, 74(Suppl 3) : iii27-iii34.
Wicha WW,Strickmann DB,Paukner S. .2019 .Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother, 74(Suppl 3) : iii11-iii18.
Wicha WW,Prince WT,Lell C,Heilmayer W,Gelone SP .2019 .Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing. J Antimicrob Chemother, 74(Suppl 3) : iii19-iii26.
. .Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia. The Medical Letter on Drugs and Therapeuticus. The Medical Letter 2019 (From issue 1581)., : .
Zeitlinger M,Schwameis R,Burian A .2016 .Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother, 71(4) : 1022-1026.
Therapeutics Announces European Medicines Nabriva,Therapeutics US .2020 .AnnouncesEuropean-Medicines-Agency-EMA-Validation-of-MarketingAuthorization-Application-for-Lefamulin. May, : .
Golan Yoav,Infections Skinstructure .2019 .Current Treatment Options for Acute Skin. Clinical Infectious Diseases, 68(S3) : S206-12.
Current Our,Therapeutics Pipeline: Lefamulin. Nabriva .2019 .. Accessed 5 September, : .
GG Briggs .2020 .Novel drugs approved in 2019. MDedgeObGyn. 27 March, : .
0

Citations

0

Downloads

12

Views